Advaxis, Inc. Reports Updated Phase 2 Cervical Cancer Trial Data at NCI/GOG Meeting
Published: Jul 30, 2012
PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, presented updated preliminary data from an ongoing randomized Phase 2 trial of ADXS-HPV being conducted in India in women with recurrent/refractory cervical cancer who have failed previous cytotoxic therapy. These data were reported on Thursday, July 26, 2012 at the Immunotherapy Subcommittee Workshop of the Gynecologic Oncology Group (GOG) meeting in Boston. The GOG is conducting a Phase 2 study of ADXS-HPV in a similar patient population in the US.